Department of Neurological Surgery

Neurosurgical Oncology Lab

Thompson Reid C. Thompson, MD

William F. Meacham Professor of Neurological Surgery
Chairman of the Department of Neurological Surgery
Director of Neurosurgical Oncology
Professor of Otolaryngology, VUMC

Publications on Pubmed

Kyle D. Weaver, MD

Assistant Professor of Neurological Surgery, VUMC
Assistant Professor of Otolaryngology, VUMC

Publications on PubMeb



Jialiang Wang, PhD

Assistant Professor of Neurological Surgery and Cancer Biology
Director, Neurosurgical Oncology Laboratory

Publications on PubMed



Lola B. Chambless, MD

Assistant Professor of Neurological Surgery, VUMC

Publications on PubMed



Neurosurgical Oncology Laboratory Location: T-4314 MCN
Laboratory Director: Jialiang Wang
Email: jialiang.wang@vanderbilt.Edu
Phone: (615) 936-6421 (x6-6421 on campus)

Neurosurgical Oncology Laboratory

The neurosurgical oncology laboratory centers on translational cancer medicine. The central objective of our laboratory is to develop innovative and transformative therapeutic strategies for the treatment of glioma and other human cancers. In the pursuit of this goal, our research focuses on frequently mutated oncodrivers, molecules implicated in cancer stem cell biology, as well as emerging epigenetic regulators as cancer drug targets. We use a wide range of molecularly characterized cancer cell lines and patient-derived xenograft tumor lines to model the diseases. We are particularly interested in drug combinations that induce synergistic drug response and circumvent drug resistance.

Click here for more information about the Neurosurgical Oncology Laboratory >>

Research Projects

A Multi-Center Collaborative Study to Determine the Sensitivity and Specificity of Plasma and Cerebrospinal Fluid Exosome EGFRvIII Detection Compared to Tissue EGFRvIII Detection by qPCR Assay of Exosomal RNA
Principal Investigator:  Reid C. Thompson, MD

Exosomes are small membrane vesicles that are thought to play important roles in intercellular communications. The goal of the study is to determine the sensitivity for detection of brain tumor specific mutations in plasma and cerebrospinal fluid (CSF) exosomes for the diagnosis and monitoring of patients with glial tumors. During the study samples of tumor, plasma and CSF are collected from glioma patients during a routine surgical procedure. Specific aims of the study include: 1) Evaluation of EGFRvIII status in plasma, CSF and tumor exosomes. 2) Determination of sensitivity and specificity of blood plasma and CSF exosome EGFRvIII detection compared to the tissue EGFRvIII detection. 3) Correlation of tissue, plasma and CSF exosomal EGFRvIII status with relevant clinical parameters.

Brain Tumor Outcomes Program
Principal Investigator: Lola Chambless MD

The Vanderbilt Brain Tumor Outcomes Program was established in 2010 with the goal of optimizing care for patients with brain tumors while deepening understanding of the pathologic principles guiding tumor development and progression.  We work with an extensive database of over 3000 patients with brain tumors of varying pathologies, prospectively collecting information regarding risk factors, treatment variables, and immediate and long term outcomes.  We also study the effect of socioeconomic factors on brain tumor prognosis and treatment in an effort to promote high quality, cost effective care.  Importantly, we also collaborate with basic scientists in the departments of cancer biology, radiology, and engineering to develop novel means of optimizing surgical resections and predicting tumor behavior.  

Characterization of cell subpopulations in Glioblastoma
Principal Investigators: Rebecca Ihrie PhD and Lola Chambless MD

Glioblastoma is a common and devastating brain tumor with a poor prognosis even in the setting of aggressive therapy.  Our hypothesis is that glioblastomas contain numerous subpopulations of cells with the ability to propagate tumor progression, leading to easy evasion of conventional therapeutic interventions.  Using novel cytometric techniques, we are comprehensively identifying functionally distinct tumor cell subsets which will offer insights into mechanisms of relapse as well as variations in tumor microenvironments.  The goal of this work is ultimately to drive fundamental shifts in the treatment of this disease.

This page was last updated January 8, 2015 and is maintained by